1. Tray N, Weber JS, Adams S. Predictive biomarkers for checkpoint immunotherapy: current status and challenges for clinical application [J]. Cancer Immunol Res, 2018, 6: 1122-1128.
2.Johnston R J, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function[J]. Cancer cell, 2014. Dec 8;26(6):923-937.
3. Xin Chen,et al. AFc-competent anti-human TIGIT blocking antibody BGB-A1217 elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models. 2021 AACR.
4. Sophia Frentzas, et al. ADVANTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumour. 2021 ASCO.
5.Rajiv Kumar,et al. AdvanTIG-105: Phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC.2022 WCLC.
6. Yan Yu,et al. AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab + Tislelizumab With Chemotherapy in Patients With Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer.2022 ESMO.